Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Conditions
Keywords
Renal diseases, Atypical hemolytic uremic syndrome, Immunoglobulin A nephropathy, Complement 5a receptor (C5aR), Complement
Brief summary
The primary objective of this study will be to evaluate the drug-drug interaction potential of CCX168 with concomitant medications, as either a perpetrator or a victim, following oral administration of CCX168 to healthy participants.
Interventions
DRUGCCX168
Administered orally.
DRUGMidazolam
Administered orally.
DRUGCelecoxib
Administered orally.
DRUGItraconazole
Administered orally.
DRUGRifampicin
Administered orally.
Sponsors
Amgen
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Male or female participants, aged 18-55 years inclusive, who are in generally good health as judged by the Investigator, whose body mass index is 19.0 to 32.0 kg/m\^2 inclusive; * Willing and able to give written Informed Consent and to comply with the requirements of the study protocol; * Negative result of the human immunodeficiency virus screen, the hepatitis B screen, and the hepatitis C screen; * Judged to be healthy by the Investigator, based on medical history, physical examination (including electrocardiogram, and clinical laboratory assessments. Participants with clinical laboratory values that are outside of normal limits and/or with other abnormal clinical findings that are judged by the Investigator not to be of clinical significance may be entered into the study; * Female participants of childbearing potential, or male participants with partners of childbearing potential may participate if adequate contraception is used during, and for at least 90 days after, any administration of study medication.
Exclusion criteria
* Pregnant or breastfeeding; * Used a prescription and/or over-the-counter medication, with the exception of ibuprofen, hormonal contraceptives, and multi-vitamins, within 14 days prior to check-in; herbal supplements must be stopped 7 days prior to check-in; * For at least 14 days prior to check-in and throughout the blood sample collection period, participants will not be allowed to eat any food or drink any beverage containing alcohol, grapefruit or grapefruit juice, apple or orange juice, vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard greens) and charbroiled meats; strenuous exercise must be stopped 4 days prior to check-in; * History within the three months prior to check-in of use of tobacco and/or nicotine containing products; * History within one year prior to check-in of illicit drug use; * History of alcohol abuse at any time in the past; * Has a history or presence of any form of cancer within the 5 years prior to check-in, with the exception of excised basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ or breast carcinoma in situ that has been excised or resected completely and is without evidence of local recurrence or metastasis; * History or presence of unexplained syncope or family history of sudden death, or any medical condition or disease which, in the opinion of the Investigator, may place the participant at unacceptable risk for study participation; * Donated or lost more than 350 mL of blood or blood products within 56 days prior to screening, or donated plasma within 7 days of dosing; * Participant's hemoglobin less than 11.5 g/dL for women or less than 13.0 g/dL for men, at screening or check-in, confirmed by a repeat measurement; * Participated in any clinical study of an investigational product within 30 days prior to dosing or within 5 half-lives after dosing; * Participant has any evidence of hepatic disease; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, or bilirubin greater than 1.5 times the upper limit of normal at screening or check-in; * Participant's white blood cell count is below the lower limit of normal at screening or check-in, confirmed by a repeat measurement; * Participant has any evidence of renal impairment; serum creatinine greater than 1.5 times the upper limit of normal at screening or check-in; * Participant's urine tested positive at screening and/or check-in for any of the following: opioids, amphetamines and methamphetamines, cannabinoids, benzodiazepines, barbiturates, cocaine, cotinine, methylenedioxymethamphetamine (MDMA or ecstasy), methadone, phencyclidine, tri-cyclic antidepressants, or alcohol (Breathalyzer test allowed for alcohol). * Participant is known as a CYP2C9 poor metabolizer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cohort B: Apparent Terminal Half Life of CCX168 | Up to Day 14 |
| Cohort B: Cmax of CCX168 | Up to Day 14 |
| Cohort B: Tmax of CCX168 | Up to Day 14 |
| Cohort B: AUC from Time 0 to infinity of CCX168 | Up to Day 14 |
| Cohort A: Maximum Plasma Concentration (Cmax) of Midazolam | Up to Day 13 |
| Cohort A: Cmax of Celecoxib | Up to Day 13 |
| Cohort A: Time of Cmax (Tmax) of Midazolam | Up to Day 13 |
| Cohort A: Tmax of Celecoxib | Up to Day 13 |
| Cohort A: Area under the plasma concentration-time curve (AUC) from Time 0 to infinity of Midazolam | Up to Day 13 |
| Cohort A: AUC from Time 0 to infinity of Celecoxib | Up to Day 13 |
| Cohort A: Apparent Terminal Half Life of Midazolam | Up to Day 13 |
| Cohort A: Apparent Terminal Half Life of Celecoxib | Up to Day 13 |
| Cohort A: Cmax of CCX168 | Day 15 up to Day 19 |
| Cohort A: Tmax of CCX168 | Day 15 up to Day 19 |
| Cohort A: AUC Over the Dosing Interval of CCX168 | Day 15 up to Day 19 |
Secondary
| Measure | Time frame |
|---|---|
| Number of Participants Experiencing Clinically Significant Changes in Laboratory Parameters | Up to Day 19 |
| Number of Participants Experiencing Clinically Significant Changes in Vital Sign Parameters | Up to Day 19 |
| Number of Participants Experiencing Adverse Events (AEs) | Up to Day 29 |
Countries
United States
Outcome results
None listed